Content about Diabetes mellitus

CHICAGO — The need for diabetes educators will rise sharply between now and 2025 as the diabetes epidemic worsens, according to a new study by the American Association of Diabetes Educators.

The study, conducted by Dobson DaVanzo & Associates, found that the need would increase by at least 60% over the next 14 years, with new career opportunities likely to emerge as private insurers and Medicare recognize the role the educators play.

IRVINE, Calif. — Medicare Part D beneficiaries showed better adherence to their oral diabetes drugs when receiving them by mail order, according to a new study.

The study, conducted on behalf of Prescription Solutions by OptumRx, the pharmacy benefit management arm of health services company Optum, and published in the Journal of Medical Economics, found that patients using mail-order pharmacy showed adherence rates of 49.7%, compared with 42.8% of those who went to retail pharmacies.

WASHINGTON — Mobile health technology may help patients, particularly those with Type 2 diabetes, better manage their condition, according to a new study conducted by University of Maryland School of Medicine researchers.

MILPITAS, Calif. — A diabetes awareness campaign, sponsored by blood-glucose monitoring systems brand OneTouch, has tapped celebrity chef Sam Talbot to help educate and inspire Americans living with diabetes.

OneTouch said Talbot, who was diagnosed with Type 1 diabetes at 12 years old, will participate in the Life First campaign by working alongside the brand to raise awareness of the importance of regular glucose testing in managing diabetes, as well as sharing strategies for success, particularly healthy eating.

BANGALORE, India — The Food and Drug Administration has approved a generic drug for diabetes made by Indian generic drug maker Strides Arcolab.

The FDA approved acarbose tablets in the 25-mg, 50-mg and 100-mg strengths. The drug is a niche drug used to treat Type 2 diabetes, Strides said.

Acarbose tablets have sales of about $21 million, according to IMS Health.

OSAKA, Japan — Japanese drug maker Takeda Pharmaceutical is reapplying for approval of two drugs to treat Type 2 diabetes after the Food and Drug Administration turned down its last applications, the company said.

Takeda announced that it resubmitted its applications for alogliptin and a drug that combines alogliptin with pioglitazone, the active ingredient in Actos, which the FDA approved in 1999.

The FDA will review the applications over the next six months, the drug maker said.

ALEXANDRIA, Va. — The American Diabetes Association has released a new guide catering to diabetic women that are planning to expand their brood and those who develop gestational diabetes during pregnancy.

NEW YORK — A study slated to appear in the Journal of Clinical Endocrinology & Metabolism, a publication of the Endocrine Society, found that adolescent girls that take the diabetes drug metformin may prevent or delay the development of polycystic ovary syndrome, a common cause of infertility.

NEW YORK — A new report published in the June issue of the Joint Commission Journal on Quality and Patient Safety found that diabetes patients can benefit from multipayer patient-centered medical homes.

INDIANAPOLIS — Eli Lilly & Co. and Disney are collaborating to produce a dedicated lifestyle website and publications for families affected by Type 1 diabetes, the two companies said Thursday.

ORLANDO, Fla. — Danish drug maker Novo Nordisk will work with advocacy group Children with Diabetes to distribute materials to children newly diagnosed with Type 1 diabetes, the two said Thursday.

The approximately 7,000 kits, designed to help them learn to live with the condition, include a booklet, savings offers and patient-support videos, and were created based on feedback from CWD members with Type 1 diabetes. Patients can order the kits through their doctors.